Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 719 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 50 mg | EXPERIMENTAL | 50 mg 3 times weekly |
| 400 mg | EXPERIMENTAL | 400 mg 3 times weekly |
| 200 mg | EXPERIMENTAL | 200 mg 3 times weekly |
| Placebo | PLACEBO_COMPARATOR | Placebo comparator associated with each active arm. (3:1 active vs placebo) |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo given 3 times weekly |
| AMG 719 | DRUG | 50 mg 3 times weekly |
| AGM 719 | DRUG | 200 mg 3 times weekly |
| placebo to AMG 719 | DRUG | Placebo dose given 3 times weekly |
* Men or women, at least 18 years of age at screening * Diagnosed with Rheumatoid Arthritis, with a disease duration of at least 24 weeks, receiving methotrexate, and having no recent history of substance or alcohol abuse
Top 20 of 28 competitors
AMG 719 is an investigational small molecule being developed for the treatment of rheumatoid arthritis. It is intended for use in patients who are also receiving methotrexate, a standard therapy for the condition.
AMG 719 is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The drug is currently in clinical development for rheumatoid arthritis.
AMG 719 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed.
AMG 719 has been studied in a completed Phase 2 clinical trial identified as NCT00038298. The trial enrolled 53 participants with rheumatoid arthritis who were also receiving methotrexate, and it was a randomized, double-blind, placebo-controlled study.
AMG 719 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for rheumatoid arthritis. The completed Phase 2 trial was designed to evaluate its effects on signs and symptoms of the disease.